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أورام الكبد اجلنينيه يف عمان
قصة جناح
فاطمه رباح، جنوى البنا، ديباىل بويان، ، ابراهيم الغيثي، حممد الهنائي، امل ال�ضباحية، نوال امل�ضايخية، ا�ضماعيل ب�ضلوي
abstract: Objectives: Primary malignant liver tumours account for more than 1% of all paediatric malignancies, 
with the most common form being hepatoblastomas (HB). Such malignancies among Arab populations have 
rarely been addressed in the literature. Using data from Oman’s sole national referral centre for childhood solid 
malignancies, this study aimed to present the nationwide Omani experience with HB over the past 21 years. 
Methods: This retrospective study reviewed the medical records of all children with HB who were managed in 
the Royal Hospital, Muscat, Oman, between January 1991 and April 2012. Clinical, radiological and laboratory 
characteristics were examined as well as treatments and outcomes. Results: During the study period, 15 patients 
with HB were treated. Of these, 10 have survived to date. Nine of the survivors were no longer receiving treatment 
and one patient still had the disease but was in a stable condition. Of the remaining five patients, three did not 
survive and two were lost to follow-up. The survival rate among patients who completed therapy was 91%. 
Conclusion: HB has an excellent prognosis in Oman. The main obstacle to improving outcomes among Omani 
patients is non-compliance with therapy.
Keywords: Hepatoblastoma; Neoadjuvant Therapy; Hepatic Cancer; Oman.
امللخ�ص: الهدف: متثل اأورام الكبد اخلبيثة االأولية اأكرث من %1 من جميع االأورام اخلبيثة عند االأطفال واكرثها �ضيوعا الورم اجلنيني. نادرا 
ماو�ضفت تلك االأورام بني ال�ضكان العرب يف االأدبيات املن�ضورة. با�ضتخدام بيانات مركز عمان الوحيد الوطني للأورام اخلبيثة ال�ضلبة  يف 
االأطفال، فاإن هدف هذه الدرا�ضة هو تقدمي التجربة العمانية الوطنية مع اأورام الكبد اجلنينية منذ 21 �ضنة. الطريقة: ا�ضتعر�ضت هذه الدرا�ضة 
الفرتة  �ضلطنة عمان، يف  م�ضقط،  ال�ضلطاين يف  امل�ضت�ضفى  املر�س وعوجلو يف  لديهم  الذين  االأطفال  الطبية جلميع  ال�ضجلت  باأثر رجعي 
2012. مت كذلك الفح�س ال�رضيري، واخل�ضائ�س االإ�ضعاعية واملخربية وكذلك العلجات والنتائج لكل احلاالت.  1991، واأبريل  من يناير 
النتائج: خلل فرته الدرا�ضة عولج 15 طفال لديهم ورم الكبد اجلنيني. ع�رضة اأطفال اأمتوا العلج ووتعافوا حتى االآن. ت�ضعة من الناجني مل 
يعودوا يتلقوا العلج وطفل واحد ال زال عنده املر�س ولكنه يف حالة م�ضتقرة. وبالن�ضبة للخم�ضة الباقني فثلثة منهم توفوا واثنني فقدوا 
عند املتابعة. كان معدل البقاء على قيد احلياة لدى املر�ضى الذين اأنهوا العلج %91. اخلال�صة: علج اأورام الكبد اجلنينية فى سلطنةعمان 
حقق جناحا عاليا. العقبة الرئي�ضة اأمام حت�ضني النتائج بني املر�ضى العمانيني هو عدم االلتزام بالعلج.
مفتاح الكلمات: اأورام الكبد اجلنينية؛ العلج املبدئي؛ �رضطان الكبد؛ عمان.
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Advances in Knowledge
- This is the first study from Oman measuring the outcomes of childhood hepatoblastoma (HB) in terms of overall survival. There are very 
few studies of this kind in the Gulf Cooperative Council (GCC) region.
Application to Patient Care 
- The results of this study will raise awareness among primary care physicians in the GCC region regarding the favourable outcomes for 
HB patients receiving treatment in Oman. An improved awareness of such positive outcomes would help improve patient counselling 
for chemotherapy and surgery. 
- Raising awareness of these positive outcomes would also help reduce patient non-compliance with treatment as well as reduce the 
number of patients who choose to opt for treatment abroad.
Approximately two-thirds of child-hood liver tumours are malignant, with hepatoblastomas (HB) representing the most 
common type.1–3 Other paediatric liver malignancies 
include sarcomas, hepatocellular carcinomas and 
germ cell and rhabdoid tumours.1,4 HB accounts for 
60–85% of all hepatic tumours in children, with an 
incidence of 0.5–1.5 per million.2,3 HB is more frequent 
in males than females, with a median age at diagnosis 
of 18 months. Only 5% of patients present beyond 
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the age of four years. The right lobe of the liver is most 
commonly affected.1 Histologically, HB is divided into 
either epithelial or mixed epithelial/mesenchymal tissue 
types, with the majority classified as epithelial and 
consisting of a mixture of embryonal and fetal cells.3 
Approximately 5% of HB cases are classified as small 
cell undifferentiated HB; this subtype is associated with 
a worse prognosis compared to other subtypes.5–7
The standard treatment for HB includes 
preoperative neoadjuvant chemotherapy, surgical 
resection and postoperative chemotherapy. The main 
determinants of clinical outcomes for patients with 
HB include the presence or absence of any metastatic 
disease and whether the tumour is resectable.1–3 In 
addition, unique histological variants of HB, such as 
the small cell subtype, have been shown to adversely 
affect survival rates.5–7 Conventional radical treatment 
(complete resection, neoadjuvant and adjuvant therapy 
and chemotherapy) is achievable in approximately 
90% of patients, with 75–85% reportedly achieving 
long-term survival.1–3 A liver transplant is the only 
remaining option for those patients with tumours 
that are rendered unresectable after a predetermined 
course of chemotherapy.8
Paediatric liver malignancies have been previously 
reported among the Omani population.9 The current 
study aimed to present the nationwide Omani 
experience with paediatric HB over the past 21 
years and to demonstrate the outcomes of standard 
treatment for HB in Oman.
Methods
This retrospective observational cohort study was 
undertaken at the Royal Hospital in Muscat, Oman. 
This large tertiary-level hospital is the only referral 
centre for paediatric solid tumours in the country. 
A retrospective review of the medical records of 
all children diagnosed with HB by pathological 
examination and managed at the hospital between 
January 1991 and April 2012 was undertaken. Data 
were collected from the records regarding patient 
demographics, clinical presentation, abdominal com-
puted tomography (CT), magnetic resonance imaging 
(MRI), chest CTs (for pulmonary lesions), surgeries 
and pathology reports of biopsies. Alpha-fetoprotein 
(AFP) levels for each patient were recorded at 
diagnosis, before and after each chemotherapy course 
(neoadjuvant and postoperative), immediately after 
any operations and at the end of the therapy. Patients 
with other primary or secondary liver tumours were 
excluded from the study.
All patients diagnosed with HB before 2005 were 
classified according to the staging system of the North 
American Cooperative Group on HB.10 Four stages 
were identified: stage I (complete resection with no 
microscopic residual disease); stage II (microscopic 
residual disease); stage III (macroscopic residual 
disease), and stage IV (distant metastases).10 All 
patients diagnosed after 2005 were classified according 
to the Pretreatment Extent of Disease (PRETEXT) 
staging system.11,12 Except for those classified as 
PRETEXT I, all patients were initially started on a 
neoadjuvant chemotherapy course to ensure safe and 
complete resection [Figure 1]. This chemotherapy 
course was repeated 3–4 times a week. After 
approximately 3–4 courses, patients were reassessed 
for tumour resectability. Once a tumour was deemed 
resectable, a standard anatomical resection with clear 
margins was attempted. Following this, postoperative 
chemotherapy was commenced. Upon completion of 
a determined number of chemotherapy courses and 
the normalisation of the patient’s AFP levels, a CT was 
performed to confirm the response of the tumour and 
to inform decisions to end the therapy. 
This study was approved by the Royal Hospital 
Ethical Committee.
Results 
A total of 15 patients were diagnosed with HB 
during the study period. The mean age at diagnosis 
was 20.5 months (range: 5–68 months) with a male 
predominance of 3:2. A palpable mass in the abdomen 
was the main presenting symptom in 12 patients 
 
Figure 1: Flowchart identifying the process of paediatric 
hepatoblastoma management at the Royal Hospital in 
Muscat, Oman.
CT = computed tomography; PRETEXT = Pretreatment Extent of 
Disease staging system; NA = neoadjuvant; PO = postoperative; 
AFP = alpha-fetoprotein. 
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(80%). Of the remaining three patients, one presented 
with constipation, fever, irritability and excessive 
crying, the second had had a fever of unknown 
origin of one month’s duration and the third patient 
presented with acute abdomen pain due to a ruptured 
tumour. One ex-preterm child with a congenital heart 
defect (tetralogy of Fallot) died before treatment could 
be administered. AFP levels were elevated in all but 
one of the patients. With the exception of two patients 
who were diagnosed by excisional biopsy, all cases of 
HB were diagnosed by a percutaneous needle biopsy 
of the liver.
With regards to CT findings, the tumour was 
observed to occupy the entire liver in seven patients, 
the right lobe only in four patients and the left lobe 
only in the remaining four patients. Pulmonary 
metastasis, in the form of multiple metastases in the 
left lung, was present in one patient at the time of 
diagnosis. After a preliminary work-up was completed, 
12 patients received preoperative chemotherapy for 
3–4 cycles starting within 7–10 days of the diagnosis. 
Upon parental request, one patient received a fifth 
cycle as a bridge therapy until surgery could be 
performed abroad. Postoperative chemotherapy was 
given in 2–5 cycles for 11 patients. 
Patients underwent the following surgical proce-
dures. One patient classified as PRETEXT I underwent 
a right hepatectomy which was not preceded by 
chemotherapy while another patient had an immediate 
surgical excision due to a ruptured tumour. Four 
patients had no surgical excisions, three were lost 
to follow-up and one was deemed unfit for surgery. 
One patient (PRETEXT IV) received chemotherapy 
followed by a liver transplant for bilateral multifocal 
HB; this procedure was performed overseas as such 
services are not currently offered in Oman. For the 
remaining nine patients, neoadjuvant chemotherapy 
rendered the tumours resectable [Figures 2A–D]. 
For follow-up surveillance after the patients were 
discharged, AFP levels were monitored monthly 
during the first year and then every three months 
for the following three years. Abdominal imaging 
using CT and ultrasound scans was done every three 
months for the first three years and on a yearly basis 
thereafter. Recurrence was detected by imaging results 
and the serial increment of AFP levels. 
Of the 15 patients examined, 10 have survived to 
date following the completion of therapy. The median 
follow-up period was 74 months (range: 1–288 months). 
The Kaplan-Meier probability of survival estimate is 
shown in Figure 3. Event-free survival ranged from 
1–20 years in nine of the patients, while one patient 
still had the disease but was in a stable condition at the 
time of writing. Among the five remaining patients, 
there were three fatalities. As mentioned earlier, one 
patient died from a cardiac comorbidity (tetralogy of 
Fallot) prior to treatment. Another patient defaulted 
twice on their treatment and later died of advanced 
 
Figure 2A–D: Computed tomography (CT) scans of (A) a hepatoblastoma tumour arising from segment 4b of the liver as 
a heterogeneous mass with hypodense areas of central necrosis and (B) the same tumour post-contrast. Subsequent CT 
scans showed (C) a marked decrease in the size of the tumour after five courses of neoadjuvant chemotherapy and (D) 
the successful treatment of the tumour with a left lobectomy. The tumour was thus rendered resectable after neoadjuvant 
chemotherapy.
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refractory disease and the third patient died after 
multiple recurrences despite receiving therapy within 
the recommended timeframe. The remaining two 
patients were non-compliant with treatment and their 
outcome was unknown as contact was lost during the 
follow-up period. Of the 11 patients who completed 
therapy, there was a single mortality, resulting in a 
survival rate of 91%.
Discussion
This study presented the nationwide Omani 
experience with paediatric HB over a 21-year period. 
The results of this study mirror previous research 
on cancer treatment in Oman, where the outcomes 
of patients with early stages and fewer adverse 
prognostic factors are comparable to those reported in 
the international literature.13 However, it is important 
to note that the management of HB in Oman has 
some unique characteristics. In some cases, patient 
treatment may be delayed for a number of reasons, 
for example if families wish to seek a second opinion 
or prefer treatment with traditional medicine (herbs 
and cautery). Choices such as these could be the result 
of social pressure from extended family. Moreover, 
one parent may request that either the other parent 
and/or the child being treated are not informed of the 
diagnosis and its implications. Patient non-compliance 
during HB treatment was a striking feature observed 
during this study; this type of behavior may have many 
negative repercussions. Parents may be reluctant to 
allow their child to continue chemotherapy or proceed 
with surgical resection after their child is in remission. 
This reluctance may be due to a fear of chemotherapy, 
which could potentially be aggravated when parents 
of children with the same condition socialise amongst 
themselves. As a result, one patient’s morbidity or 
mortality might negatively affect treatment decisions 
for another when these parents share their experiences.
The incidence and survival rate of HB among Arab 
populations has rarely been discussed in the literature. 
One report from the United Arab Emirates (UAE) 
detailed 11 HB cases with a mortality rate of 45% 
following the death of five patients.14 The current study 
noted a survival rate of 91% in Oman, a comparison 
which is favourable against that of the UAE. This rate 
is consistent with previously reported studies among 
other countries.1,5,8 However, it is remarkable that this 
rate was achieved despite the fact that bilateral lobar 
involvement of the liver was most prevalent among the 
current study’s patient population. This is in contrast 
to other research which indicates that right lobar 
involvement is most common.1,2,8,7 
A study performed in El Salvador found that the 
severity of neutropaenic fever episodes in paediatric 
patients was associated with a low socioeconomic 
status or residence in rural areas.15 Gavidia et al. 
reported significant relationships between maternal 
illiteracy, low household income and anticipated 
travel time to the hospital on the outcomes of febrile 
neutropaenia.15 Similarly, the number and severity 
of febrile neutropenia episodes in the current study 
population were influenced by parental education, 
socioeconomic status and travel time.
Although HB is rare, it has gained attention in recent 
decades due to its incidence, which has increased by 
5% annually.8 As can be seen by the minimal number 
of HB patients observed in the present study despite 
the lengthy study period, the incidence of HB in Oman 
is low. However, the real incidence of this disease in 
Oman may be underestimated. Some patients may 
have died before diagnosis, while others may have 
been treated overseas. Nevertheless, considering 
a population of approximately three million,16 the 
incidence of HB in Oman is almost identical to reported 
annual incidence rates of 0.5–1.5 cases per million.2,3,8 
However, the findings of the current study did not 
match those of other researchers regarding average 
patient age at presentation (20.5 versus 18 months 
in other studies).1–3,5 It is likely that this difference is 
attributable to a delay among families seeking medical 
advice for their child.
There is mounting evidence suggesting an 
association between HB and prematurity.1,17,18 The 
present study provides further evidence to support 
this association as one of the studied patients was 
an ex-preterm infant. Interestingly, several studies 
have observed that ex-preterm infants do not present 
with tumours at a younger age than term infants.17,18 
It has been theorised that observed increases in HB 
incidence could partly be due to increasing survival 
 
Figure 3: Kaplan-Meier probability of survival estimate 
curve for the paediatric hepatoblastoma cases identified 
over a 21-year period (N = 15).
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rates among extremely premature infants.1 Moreover, 
increases in HB incidence could also be a result of the 
adverse effects of neonatal intensive care.17,18
Regarding the laboratory findings at diagnosis, 
only one case in the present study had low AFP levels 
at presentation with histopathology indicating small 
undifferentiated cell HB. It has been found that this 
pathological subtype constitutes 5% of HB cases and 
has a poor prognosis, especially when coupled with 
low AFP levels at diagnosis.5,6,19,20 
Chemotherapy played a pivotal role in inducing 
tumour resectability in the current study. A total of 
10 patients had tumours that were initially inoperable. 
However, preoperative neoadjuvant chemotherapy 
enabled the tumours to be resected in nine of these 
patients. Surgical resection is the mainstay of HB 
therapy.1,6 Approximately 10–20% of all HB cases 
involve the entire liver, are extensively multifocal or 
exhibit macrovascular invasion. Such cases require a 
liver transplant to achieve long-term survival, which 
ranges from 55–100% as reported in several single 
centre series.8,21
Although the HB survival rate in Oman was 
determined to be 91%, this good prognosis is not well 
known among primary care physicians. Thus, some 
families of HB patients may opt for overseas treatment 
or default on therapy without realising the significant 
impact this may have on the patient’s chances of 
survival. A greater awareness of the success rate for 
HB therapy in Oman is required among treating 
physicians and their patients. The families of survivors 
should be encouraged to share their experiences with 
successful HB treatment in Oman.
Conclusion
Patients diagnosed with HB in Oman have an excellent 
prognosis, with the results of this 21-year study 
demonstrating a 91% survival rate. However, there is 
a need for greater awareness of this positive prognosis 
among primary care physicians in Oman in order to 
overcome patient non-compliance. Prevention of 
patient non-compliance could have a significant impact 
on the disease outcome and may be accomplished in 
collaboration with the families of survivors. 
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